Calidi Biotherapeutics, Inc.
CLDI· NYSE
CLDICalidi Biotherapeutics, Inc.
Filed Nov 14, 2023 · 10-Q · 45 days after period end · 0001493152-23-041122
| Metric | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|
| Net Income | -$2.02M | -$5.36M | -$823.29K |
| EPS Diluted | -$1.41 | -$0.63 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Calidi Biotherapeutics, Inc. · CIK 1855485 · Engraved from SEC EDGAR
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end
